Stay updated on CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab

Sign up to get notified when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.
Latest website image capture
Clouds background image

Latest updates to the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T06:05:58.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version of a clinical trial, with significant changes in the trial's structure and details, including the addition of specific cancer types and the number of patients in each cohort. The principal investigator's name has also been updated.
    Difference
    40%
    Check dated 2025-04-16T17:00:49.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 14, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.
    Difference
    0.3%
    Check dated 2025-04-09T12:55:19.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:57:48.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T22:49:46.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T16:00:16.000Z thumbnail image

Stay in the know with updates to CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab

Enter your email address, and we'll notify you when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.